A Phase 2 interventional study of Methotrexate and Pentoxifylline in Rheumatoid Arthritis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Tanta University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Arthritis, Rheumatoid by Tanta University — 11 open to participants now, 11 under way, 3 of them phase 3. Arthritis, Rheumatoid · Tanta University.
Among the 15 studies in Arthritis, Rheumatoid by Tanta University, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 10th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →11 of the 15 studies in Arthritis, Rheumatoid by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18–60
Tanta University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 4
First in 2019; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 63 across the 14 interventional studies, 30 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Arthritis, Rheumatoid by Tanta University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800351Phase 3Tanta UniversityNicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis | 2027-02 |
| NCT07401732Tanta UniversityDysphagia in Rheumatoid Arthritis | 2026-11 |
| NCT06998628Tanta UniversityPentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis | 2027-05-30 |
| NCT07901309Tanta UniversityEfficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis | 2027-06-30 |
| NCT07745426Tanta UniversityClinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Arthritis, Rheumatoid by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will receive the traditional therapy of RA for three months.
Drug: Methotrexate
will receive 400 mg pentoxifylline two times daily plus the traditional therapy of RA for three months.
Drug: Methotrexate · Drug: Pentoxifylline
Methotrexate (MTX) is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for including breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Methotrexate is also used to treat rheumatoid arthritis and other inflammatory conditions.
Pentoxifylline (also known as oxpentifylline) is a methylxanthine derivative with strong hemorrheologic effects. In the United States, it is primarily used to treat intermittent claudication. Studies in both humans and animals have demonstrated that pentoxifylline therapy induces various physiological changes at the cellular level
change in Disease Activity Score (DAS28)
Calculation of 28-joint count Disease Activity Score (DAS28) using C- reactive protein level (CRP) according to the following formula: DAS28-CRP = \[0.56\*√ (tender joint count) + 0.28\*√ (swollen joint count) + 0.36\*ln (CRP+1)\] \*1.10 + 1.15\] will be done where sever disease activity ≥ 5.1, moderate disease activity from 3.2 to 5.1, mild disease activity from 2.6 to 3.2, and remission \<2.6.
Time frame: 3 months
Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.
Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 23 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion May 2026 → May 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pentoxifylline